Anti-CD73 in combination with anti-PD-L1 therapy enhanced T cell response via upregulation of the number of CD8+ T cells and promotion of TNF-α and IFN-γ production in EGFR-mutant NSCLC, leading to inhibition of tumor growth (Tu et al., 2022). Here, CD8A is linked to neoplasm.